Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome

References

• Baillargeon JP, Nestler JE. 2006. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? The Journal of Clinical Endocrinology and Metabolism 91:22–24.
   PubMed Web of Science ®Google Scholar
• Barber TM, McCarthy MI, Wass JA, Franks S. 2006. Obesity and polycystic ovary syndrome. Clinical Endocrinology 65:137–145.
   PubMed Web of Science ®Google Scholar
• Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yıldız BO. 2016. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction 31:2841–2855.
   PubMed Web of Science ®Google Scholar
• Burtis CA, Ashwood ER. 1994. Tietz textbook of clinical chemistry, 2nd ed. Philadelphia, PA: Saunders. p. 1850–1851
   Google Scholar
• Cai C, Lin M, Xu Y, Li X, Yang S, Zhang H. 2016. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study. BMC Med 14:165.
   PubMed Web of Science ®Google Scholar
• Casadei L, Fanisio F, Sorge RP, Collamarini M, Piccolo E, Piccione E. 2018. The diagnosis of PCOS in younginfertilewomenaccording to different diagnostic criteria: the role of serum anti-Müllerian hormone. Archives of Gynecology and Obstetrics 298:207–215.
   PubMed Web of Science ®Google Scholar
• Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. 2008. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Human Reproduction 23:952–957.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang GX, Ma SL, Jung DY, Ha H, Altamimi T, et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders. Molecular Metabolism 2017;6:863–872.
   PubMed Web of Science ®Google Scholar
• Cui Y, Shi Y, Cui L, Han T, Gao X, Chen ZJ. 2014. Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome. Fertility and Sterility 102:230–236.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. 2006. Indices of low-grade inflammation in polycystic ovary syndrome. Annals of the New York Academy of Sciences 1092:175–186.
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. 1961. Clinical assessment of body hair growth in women. The Journal of Clinical Endocrinology and Metabolism 21:1440–1447.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Richelsen B, Bruun JM. 2009. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clinical Endocrinology 71:652–658.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Goldenberg N, Pranikoff J, Khan Z, Padda J, Wang P. 2013. Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. Current Medical Research and Opinion 29:55–62.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Goldenberg N. 2018. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism 92:108–120.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Akamatsu H, Kawashima M. 2008. Establishment of grading criteria for acne severity. The Journal of Dermatology 35:255–260.
   PubMed Web of Science ®Google Scholar
• La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, et al. 2004. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Human Reproduction 19:2738–2741.
   PubMed Web of Science ®Google Scholar
• La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. 2004. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertility and Sterility 82:970–972.
   PubMed Web of Science ®Google Scholar
• Legro RS. 2012. Obesity and PCOS: implications for diagnosis and treatment. Seminars in Reproductive Medicine 30:496–506.
   PubMed Web of Science ®Google Scholar
• Lim SS, Davies MJ, Norman RJ, Moran LJ. 2012. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 18:618–637.
   PubMed Web of Science ®Google Scholar
• Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. 2016. Criteria, prevalence and phenotypes of polycystic ovarian syndrome. Fertility and Sterility 106:6–15.
   PubMed Web of Science ®Google Scholar
• Ma Y, Gao M, Liu D. 2016. Preventing high fat diet-induced obesity and improving insulin sensitivity through neuregulin 4 gene transfer. Science Report 6:26242.
   PubMed Web of Science ®Google Scholar
• Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. 2009. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Human Reproduction 24:2917–2923.
   PubMed Web of Science ®Google Scholar
• Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H. 2007. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. The Journal of Clinical Endocrinology and Metabolism 92:240–245.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19–25.
   Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L, 2010. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medcine 8:41.
   PubMed Web of Science ®Google Scholar
• Temur M, Calan M, Akşit M, Yılmaz Ö, Çift T, Akselim B, et al. 2017. Increased serum neuregulin 4 levels in women with polycystic ovary syndrome: a case-control study. Ginekologia Polska 88:517–522.
   PubMed Web of Science ®Google Scholar
• Visser JA, de Jong FH, Laven JS, Themmen AP, 2006. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction (Cambridge, England) 131:1–9.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. 2014. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. International Journal of Surgery 12:1495–1499.
   PubMed Web of Science ®Google Scholar
• Vonbank A, Saely CH, Rein P, Drexel H, 2013. Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease. Cardiovascular Diabetology 12:106.
   PubMed Web of Science ®Google Scholar
• Wang GX, Zhao XY, Lin JD, 2015. The brown fat secretome: metabolic functions beyond thermogenesis. Trends in Endocrinology & Metabolism 26:231–237.
   PubMed Web of Science ®Google Scholar
• Wang GX, Zhao XY, Meng ZX, Kern M, Dietrich A, Chen Z, et al. 2014. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nature Medicine 20:1436–1443.
   PubMed Web of Science ®Google Scholar
• Yan PJ, Xu Y, Wan Q, Feng J, Li H, Gao CL, et al. 2017. Decreased plasma neuregulin 4 concentration is associated with increased high-sensitivity C-reactive protein in newly diagnosed type 2 diabetes mellitus patients: a cross-sectional study. Acta Diabetologica 54:1091–1099.
   PubMed Web of Science ®Google Scholar
• Zeng XL, Zhang YF, Tian Q, Xue Y, An RF, 2016. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. Medicine (Baltimore) 95:e4526.
   PubMed Web of Science ®Google Scholar